NASH: Pointers for Pharma from the Patient's Perspective
Read the article here.
The disease was first identified in the 1980s. Since then, its prevalence has grown rapidly in line with that of NAFLD, now one of the most common liver diseases worldwide. These trends reflect a growing epidemic of type 2 diabetes and obesity worldwide. One recent meta-analysis found the global prevalence of NAFLD to be around 25%, while the global prevalence of NASH is estimated at 3-5%.